BioSpace News Archive

Quad M Solutions Inc. (OTC.PK: MMMM) has appointed Joseph Frontiere and Douglas Cole to its Board of Directors with Mr. Frontiere appointed its new Interim CEO.

Blue biotechnology refers to the use of marine bio-resources as the source of biological applications.

Gene expression is a technique through which genetic instruction are used for synthesizing gene products.

Researchers with Google Health, Naval Medical Center San Diego (NMCSD), and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) have developed artificial intelligence (AI) models to predict status of three important biomarkers from routine breast cancer haematoxylin and eosin-stained slides, enabling better understanding of the links between biological factors for treatment and the structure (morphology) of a tumor.

Wise Therapeutics (Wise), a developer of game-based digital therapeutics, announced the results of a study conducted in collaboration with NYU Langone Health, published in Frontiers in Neurology.

Expansion sought after for computerized research facilities across topographies with ascend in notoriety of lab computerization gear significantly drives the market development.

Increase in geriatric population, surge in prevalence of rare diseases, rise in usage of immunoglobulins in areas of medicine, and upsurge in number of plasma collection centers drive the growth of the global plasma fractionation market.

Milestone Scientific Inc. today announced it will host a conference call at 11:00 A.M. Eastern Time on Monday, August 16, 2021 to discuss the Company’s financial results for the second quarter ended June 30, 2021, as well as the Company’s corporate progress and other developments.

Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced the appointment of Moises V. “Moe” Vela, Jr. to its business advisory board.

Atreca, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, announced financial results for the second quarter ended June 30, 2021, and provided an overview of recent developments.